Please assess the completion status of the following clinical trial:

Trial Title: Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has had a documented colonoscopy to the cecum, by a study physician, with adequate preparation resulting in diagnosis and clearance of an adenomatous polyp(s) within 24 weeks prior to study entry; the 24- week period begins from the time of colonoscopy, which had resulted in full visualization of colon/rectum or the time of removal of adenoma which ever had occurred first~* At the baseline colonoscopy, the subject must have one of the following documented:~  * One adenomatous polyp \> 6 mm;~    * If the colonoscopy report says that a 6 mm polyp was removed, and the local pathology report confirms that this adenoma was AT LEAST 6mm in any dimension, the subject is eligible~   * If the colonoscopy report says that the 6mm polyp was removed, and the local pathology report says that multiple fragments of adenoma were obtained, the subject is eligible~   * If the colonoscopy report says that a 6mm polyp was removed, but the pathologist measured this as 5mm or less in greatest dimension, the subject is NOT eligible~ * Two or more adenomatous polyps of any size documented by local pathology report plus colonoscopy report; or~ * One adenomatous polyp of any size and a documented history of adenomatous polyp(s); if the colonoscopy report indicates that polyps of any size were left in the subject, the subject is NOT eligible; if the colonoscopy report says that all visible adenomas were removed, the subject is eligible.~If the colonoscopy report does not specifically state that all visible adenomas were removed, but does not describe any adenomas that were left in, the subject is eligible~* The subject is willing to abstain from chronic use of all NSAIDs or COX-2 inhibitors, excluding aspirin (cardioprotective doses of less than or equal to 325mg po QOD or 162.5mg po QD) for the duration of the study; chronic use of NSAIDs is defined as a frequency 1 week (7 consecutive days) for more than three weeks per year~* The subject is willing to limit aspirin use to less than or equal to 325mg po QOD or 162.5mg po QD for the duration of the study~* The subset of subjects undergoing SEB analysis will be required to abstain from any aspirin use for the duration of the study~* The subjects' anticipated use of oral/intravenous corticosteroid must be less than 2 weeks over a 6 month period~* The subject's anticipated use of orally inhaled steroid must be less than 4 weeks over a 6 month period; if nasally inhaled steroid use is anticipated, the subject agrees to use mometasone (Nasonex) only. Use of mometasone is not restricted (all other nasal steroids are prohibited); subjects may change to mometasone, but must have discontinued the previous nasal steroid for at least 30 days prior to randomization~* If a subject is female and of child-bearing potential (women are considered not of childbearing potential if they are at least 2 years post-menopausal and/or surgically sterile), she:~  * Has been using adequate contraception (abstinence, IUD, birth control pills, or spermicidal gel with diaphragm or condom) since her last menses and will use adequate contraception during the study,~ * Is not lactating, and~ * Has a documented negative serum or negative urine pregnancy tests within 14 days prior to study entry~* The subject must sign and date the informed consent statement~* Hemoglobin level of greater than 11.5 (both men and women)~* WBC count greater than 3000/mm\^3~* Platelet count greater than 125,000~* Creatinine =\< 1.5 X ULN~* AST =\< 1.5 X ULN~* ALT =\< 1.5 X ULN~* Total bilirubin =\< 1.5 X ULN, unless the subject has Gilbert's disease, for which total bilirubin must be =\< 2.0 X ULN~* Inclusion Criteria for the 2-year post-treatment safety assessment:~  * Subjects who were enrolled in the Year-3 study will be eligible for a 2-year post-treatment safety assessment~ * Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 2-year post-treatment safety assessment:~    * Have been enrolled on the 3-year randomized portion of the clinical trial~   * Willingness to continue with follow-up annual contacts for safety data collection~   * The subject has signed and dated an addendum (Subject Letter) to the informed consent document prior to performing any post-treatment safety assessment procedures~* Inclusion Criteria for Post-treatment Follow-up Colonoscopy:~  * All Subjects who completed Year 3 colonoscopy will be eligible for a post-treatment follow up colonoscopy 2 years after Year 3 colonoscopy~ * Subjects must meet all of the following inclusion criteria to be eligible for follow up colonoscopy:~    * Completion of study treatment (3 years of study drug or on study drug on December 17, 2004) on the 3-year randomized portion of the clinical trial~   * Willingness to continue with follow-up contacts every 6 months for collecting concomitant medications use data and end-of-study colonoscopy at Year 5~   * The subject has signed and dated a separate informed consent document prior to performing any follow-up procedures; while delay in obtaining consent is not optimal, patients may be consented and entered into the post-treatment follow-up study at any time prior to their Year 5 colonoscopy but no later than 1Q2007~Exclusion Criteria:~* The subject has a history of Familial Adenomatous Polyposis or Hereditary Non-Polyposis Colorectal Cancer (as defined by the Amsterdam Criteria)~* The subject has a history of inflammatory bowel disease~* Subject has a chronic or acute renal or hepatic disorder or a significant bleeding disorder~* The subject has a history of hypersensitivity to COX-2 inhibitors, NSAIDs, salicylates, or sulfonamides~* The subject has a history of large bowel resection, except appendectomy~* The subject has used NSAIDs, excluding aspirin at any dose at a frequency equal to or greater than three times per week during the two months prior to randomization~* The subject used aspirin at a dose exceeding 325mg QOD or 162.5mg QD at a frequency equal to or greater than three times per week during the two months prior to study entry~* For SEB measurement participants only: the subject used any dose of aspirin at a frequency greater than once weekly during the two months prior to study entry~* The subject used oral/intravenous corticosteroids for more than 2 weeks in past 6 months~* The subject used orally inhaled corticosteroids for more than 4 weeks in past 6 months and/or the subject has used nasally inhaled corticosteroids (except mometasone) within the last month prior to randomization~* The subject has treatment for a gastrointestinal ulcer in the past month prior to study entry~* The subject has a history of invasive cancer within the past five years (excluding non-melanoma skin cancer)~* The subject has received any investigational medication within 30 days prior to randomization or is scheduled to receive an investigational drug other than celecoxib during the course of the study~* The subject is unable to return for follow-up tests~* The subject participated in the study previously and had been withdrawn~* Subjects whom, in the opinion of the Lead PI, Institutional PI, or Subinvestigator are not appropriate candidates for Study participation~* Subjects currently using triazole or azole antifungal agents (i.e., fluconazole) or lithium

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (celecoxib) (Type: EXPERIMENTAL): Patients receive celecoxib twice a day for 3 years.
- Arm II (placebo) (Type: PLACEBO_COMPARATOR): Patients receive placebo twice a day for 3 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete